Hemay Pharmaceutical

Executive Summary

Hemay Pharmaceutical is a private Chinese biopharmaceutical company dedicated to developing novel small molecule therapies for dermatology and oncology. Founded in 2020 and based in Tianjin, the company employs a patient-centered R&D approach to create safer, more effective, and economical drugs. Its pipeline features clinical-stage candidates targeting prevalent conditions such as psoriasis, atopic dermatitis, and various cancers. Despite being early-stage (Phase 2), Hemay has the potential to address significant unmet medical needs in China and globally. The company's focus on dermatology, a large and growing market, positions it well for future growth, though it faces intense competition and regulatory hurdles. With no disclosed funding or valuation, the company's financial stability remains uncertain, but its targeted therapeutic areas offer clear commercial opportunities.

Upcoming Catalysts (preview)

• Q2 2027Phase 2 data readout for lead psoriasis candidate40% success
• Q4 2026Regulatory filing for atopic dermatitis candidate in China30% success
• Q1 2027Partnership or licensing deal for oncology candidate25% success